A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with C797S mutation or is newly diagnosed with CNS metastasis with EGFR Del19 or L858R mutation

NCT Number	NCT07206498
Lead Sponsor	Wayshine Biopharm, Inc.
Conditions	Non Small Cell Lung Cancer (NSCLC)
Enrollment	48 participants
Start Date	2025-10-17
Primary Completion	2028-10-14 (estimated)
Study Completion	2029-10-14 (estimated)
Updated on ClinicalTrials.gov	2025-11-28